Silver Book Fact

“A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans age 65 and older with Alzheimer’s disease from 5.6 million to 4 million by 2020.  As a result, 1.6 million Americans who would be expected to have the condition in 2020 would be free of the condition.  In addition, five years later, in 2025, 2.7 million Americans–42 percent of the 6.5 million people who would be expected to have Alzheimer’s in that year–would be disease free.  The biggest effect would be in 2050 when 5.8 million people–43 percent of the 13.5 million Americans who would be expected to have Alzheimer’s without the breakthrough–would not have the condition.”

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Medicare Costs, 5-Year Delayed Onset  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…